First Manhattan’s Stoke Therapeutics STOK Stock Holding History

First Manhattan’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-150	Closed	-$1K	–	1782
2022 Q3	$1K	Hold	150	–	–	﹤0.01%	1486
2022 Q2	$1K	Hold	150	–	–	﹤0.01%	1513
2022 Q1	$3K	Hold	150	–	–	﹤0.01%	1463
2021 Q4	$3K	Hold	150	–	–	﹤0.01%	1458
2021 Q3	$3K	Hold	150	–	–	﹤0.01%	1494
2021 Q2	$5K	Hold	150	–	–	﹤0.01%	1395
2021 Q1	$5K	Hold	150	–	–	﹤0.01%	1346
2020 Q4	$9K	Hold	150	–	–	﹤0.01%	1161
2020 Q3	$5K	Hold	150	–	–	﹤0.01%	1204
2020 Q2	$3K	Hold	150	–	–	﹤0.01%	1300
2020 Q1	$3K	Buy	+150	New	+$3.71K	﹤0.01%	1279

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

First Manhattan's STOK Position: Q4 2022 in Review

First Manhattan sold out of Stoke Therapeutics (STOK) in Q4 2022, closing a stake of 150 shares — an estimated $1K sold.

First Manhattan first reported a position in STOK in Q1 2020 and held it in 11 quarters. The position peaked at $9K in Q4 2020. 107 funds tracked by Wall St. Rank hold STOK as of Q4 2022.

First Manhattan reported no remaining Stoke Therapeutics position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 150 Stoke Therapeutics shares in Q4 2022, an estimated $1K.
First Manhattan first reported a position in Stoke Therapeutics in Q1 2020 and held it in 11 quarters.
First Manhattan's Stoke Therapeutics position peaked at $9K in Q4 2020.
107 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.